Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Treatment of Refractory Breast Cancer Based on Organoid Drug Sensitivity Results

NCT06438055 is registered in ClinicalTrials.gov with Tianjin Medical University Cancer Institute and Hospital as lead sponsor.

NCT NCT06438055
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06438055 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Treatment of Refractory Breast Cancer Based on Organoid Drug Sensitivity Results
Lead sponsor
Tianjin Medical University Cancer Institute and Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
June 30, 2024
Completion date
June 30, 2026
Enrollment
40 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

refractory breast cancer